Skip to main content

Nacalai to Distribute TriLink Tools in Asia

NEW YORK (GenomeWeb News) – TriLink BioTechnologies said today that Nacalai USA will distribute TriLink's nucleic acid products in certain Asian countries.

Under the agreement, Nacalai will distribute TriLink's technologies in Japan, Singapore, South Korea, and Taiwan.

TriLink's product offerings include custom oligonucleotides, modified nucleoside triphosphates, and its CleanAmp PCR products for the diagnostic and OEM markets.

Nacalai USA is the San Diego-based subsidiary of Nacalai Tesque, of Kyoto, Japan.

The company said that the agreement will give the Asian market access to modified nucleic acid products to further advance research efforts in areas such as molecular biology and proteomics.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.